anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dysregulated macrophage responses and changes in tissue metabolism are hallmarks of chronic inflammation in the skin. However, the metabolic cues that direct and support macrophage functions in the skin are poorly understood. Here, we show that during sterile skin inflammation, the epidermis and macrophages uniquely depend on glycolysis and the TCA cycle, respectively. This compartmentalisation is initiated by ROS-induced HIF-1α stabilization leading to enhanced glycolysis in the epidermis. The end-product of glycolysis, lactate, is then exported by epithelial cells and utilized by the dermal macrophages to induce their M2-like fates through NF-κB pathway activation. In addition, we show that psoriatic skin disorder is also driven by such lactate metabolite-mediated crosstalk between the epidermis and macrophages. Notably, small-molecule inhibitors of lactate transport in this setting attenuate sterile inflammation and psoriasis disease burden, and suppress M2-like fate acquisition in dermal macrophages. Our study identifies an essential role for the metabolite lactate in regulating macrophage responses to inflammation, which may be effectively targeted to treat inflammatory skin disorders such as psoriasis.
Headache, blurring of vision, confusion, drowsiness, syncope, fatigue, edema, thrombophlebitis, hematemesis, diarrhea, and pain. These did not appear to be dose related and were not unequivocally drug related. They may have been due to the primary or metastatic disease processes. Malaise and asthenia have been reported as part of postmarketing surveillance. Bladder fibrosis/contraction has been reported with intravesical administration (see PRECAUTIONS). 

To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals, Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Liposomes according to the present invention for a pulmonary administration, advantageously comprising at least a first and at least a second phospholipid as well as cholesterol and at least one active compound and/or dye, whereby the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably chosen from the group of DMPC, DPPC, DPPE. It is favorable if the first and the second phospholipid are present in a molar ratio ranging from 0.5:1 to 10:1, preferred in a molar ratio of 6:1 to 2:1, particularly preferred is a molar ratio of 3:1. In addition favorable is if the molar ratio of phospholipids to cholesterol ranges between 10:1 and 1:1, preferably between 6:1 and 3:1, particularly preferred is a molar ratio of 4:1. Furthermore evident is that the second phospholipid is preferably DMPC or DPPE, particularly preferred DPPE. The size of the liposomes advantageously ranges between 0.05 µm and 5 µm, preferred between 0.2 µm and 2.0 µm, and the mass median aerodynamic diameter of aerosol particles which contain the liposomes is between 1 µm and 6 µm, preferred between 1.5 µm and 5 µm, particularly preferred between 2 µm and 4.5 µm. Particularly advantageous is also if the stability of liposomes during nebulization is higher than 50 %, preferred higher than 75 %, particularly preferred higher than 80 %. Furthermore advantageous is if the phase transition temperature is higher than 37°C, preferred higher than 45°C, and particularly preferred higher than 50°C.
A composition containing Geranium nepalense sub sp. thunbergii extract for anti-inflammation is provided to prevent and treat inflammatory diseases through the inhibition of NF-kB, cyclooxygenase-2, and chondroitinase. A pharmateutical composition for anti-inflammation comprises Geranium nepalense sub sp. thunbergii extract having the anti-inflammatory effect suppressing the NF-kappaB, cyclooxygenase-2, and chondroitinase. The Geranium nepalense sub sp. thunbergii extract is obtained by washing, pulverizing, extracting in water at 110°C for three hours, filtering, compress-concentrating, and freeze-drying. The daily dose of the composition is 1-30 mg/kg, and administrated once or several times. A fermented milk, beverage, or health functional food for preventing the inflammation comprises the Geranium nepalense sub sp. thunbergii extract.
Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
The application relates to a diagnostic data transmission method, a diagnostic data transmission device, a computer device and a storage medium for diagnostic equipment based on a two-dimensional code mode. The method comprises the following steps: the equipment manufacturer applies for registering equipment of a certain model to the MedRhein cloud platform and negotiates a Speed Dial message data field format. The message should be as short as possible to improve the readability of the two-dimensional code on the low-resolution screen; the MedRhein cloud platform distributes RSA public keys for the equipment of the model and distributes API keys; the device provides a data export function in the form of a two-dimensional code and displays the two-dimensional code; a user scans a two-dimensional code by using a MedRhein APP and reads a scanning result through a MedRhein cloud platform; the MedRhein cloud platform decrypts the ciphertext by using the private key, interprets the message according to the equipment model, and judges and stores the result and the database. By adopting the method, the diagnosis data can be converted into the two-dimension code according to a specific protocol without depending on the traditional communication module and interface and in a two-dimension code mode. The device displays the data on a display screen or prints the data on a test result bill in the form of a single interface (two-dimensional code). Thereby saving the development cost of software and hardware of the equipment.
This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
This is a randomized double-blind placebo-controlled proof-of-concept trial. A total of 30 RA patients will be asked to join the study. They will be randomized to receive capsular FMT + standard of care or placebo + standard of care. There will be four study visits in total: Baseline, FMT administration, 6- and 12-week follow-up visits. Follow-up visits will consist of assessment by a rheumatologist, completion of surveys, and collection of biologic samples.

Samples for the study are stool, urine and blood. Blood and fecal samples will be collected at baseline, 6 weeks and 12 weeks. Urine samples will be collected at baseline and 6 weeks.
PROBLEM TO BE SOLVED: To prepare a hair cosmetic having suitable hair fixing power and a power for keeping the fixed hair, capable of providing natural gloss and soft touch and hardly causing stickiness by formulating a specific polyether compound and a mucopolysaccharide. SOLUTION: This hair cosmetic contains a polyether compound obtained by carrying out an addition polymerization of 1-10 mol. ethylene oxide to a main chain obtained by carrying out the addition polymerization of 20-90 mol. propylene oxide to a polyhydric alcohol, formulated in combination with a mucopolysaccharide. The formulating amount of the polyether is 1-50 wt.%, preferably 10-40 wt.% based on the whole amount of the hair cosmetic. The mucopolysaccharide is preferably hyaluronic acid, chondroitin tetrasulfate, chondroitin octasulfate, etc. The formulating amount of the mucopolysaccharide is 0.001-10 wt.%, preferably 0.01-5 wt.% based on the whole amount of the hair cosmetic.
INTRODUCTION: Chronic ankle instability (CAI), a common seqeula to ankle injury is characterized by a variety of sensorimotor deficits extending beyond the previously injured limb. Cutaneous reflexes have been identified as a potential contributor to these functional limitations with recent studies identifying alterations in reflex patterns following sural nerve stimulation among those with CAI. To date, no studies have measured cutaneous reflexes of the unaffected limb in this population, therefore, the objective of this study was to measure contralateral cutaneous reflexes during gait in individuals with unilateral CAI and healthy controls.
METHODS: Muscle activity of 6 lower limb muscles was measured in nineteen participants while receiving random, non-noxious sural nerve stimulations during a walking task.
RESULTS: Control reflex patterns were generally well-aligned with previous literature while CAI patterns varied from controls in several muscles throughout the gait cycle. Namely, a lack of lateral gastrocnemius facilitation during late stance and medial gastrocnemius inhibition at midstance. Additionally, a lack of significant BF facilitation throughout contralateral swing was noted. These results indicate reflex alterations extend beyond the affected limb in those with unilateral CAI indicating changes at the spinal level following lateral ankle sprains (LAS). Considering the symptom variability in CAI, the lack of significant reflexes exhibited by the CAI group may be due to increased variability in motor output between subjects or between stimulation trials.
CONCLUSIONS: These findings highlight the importance of identifying reflex alterations arising from LAS and subsequently treating these limitations through rehabilitation targeting systemic neural pathways rather than local deficits.
Type 1 diabetes mellitus (TDM) is a chronic autoimmune disease. that affected carbohydrate metabolism and caused by insulin insufficiency resulting in increased blood glucose. It's one of the most common endocrine and metabolic conditions in childhood. There's 9 million people live with T1DM worldwide according to International Diabetes Federation. In Egypt, 1 in 98 families are impacted and the disease is growing at 6.7% each year. Living with T1DM has been associated with a significant impact on a person's social, mental, and psychological quality of life (QoL). as the individual must adopt blood glucose monitoring, use of injections or diabetes technology for insulin regulation, diet restrictions, and exercise. Also, there's increased risk of developing micro-and macro-vascular complications that result in morbidity and mortality in Long-term uncontrolled DM. therefore, these children and adolescents with T1DM have an increased risk of psychiatric comorbidities like depression, anxiety and sleep disorders, depression is one of the most common disorders. They appear to have a greater incidence of depression, anxiety and poor health-related quality of life (HRQoL) compared to their healthy peers. This is associated with suboptimal diabetes outcomes and better metabolic control has been found to correlate with better quality of life. This occurs especially when diagnosed at earlier age of onset, history of severe hypoglycemia and chronic hyperglycemia. There are no available studies that assess the presence of psychiatric comorbidities in T1DM in our locality.
The present invention provides a herpes virus in which a non-essential gene for replication is inactivated. More particularly, the present invention provides a herpes virus in which a non-essential gene for replication present in a UL or US region is inactivated. More preferably, the non-essential gene for replication contains US3 or UL56. The herpes virus may be preferably a herpes simplex virus, and more preferably herpes simplex virus 1 or herpes simplex virus 2. The present invention provides a method, composition and use for treating various diseases or disorders including tumor and infectious diseases. The present invention also provides a method, composition and use for activating a prodrug.
This arm combines use of AD plus the Learn. Engage. Act. Process (LEAP) program. LEAP is a 6-month quality improvement coaching program plus a 6-month monthly follow-up.
Liver fibrosis is a reversible damage-repair response, the pathological features of which mainly include damage to hepatocytes, sinusoid capillarization, hepatic stellate cells activation, excessive accumulation of extracellular matrix and inflammatory response. Although some treatments (including drugs and stem cell therapy) for these pathological features have been shown to be effective, more clinical trials are needed to confirm their effectiveness. In recent years, nanomaterials-based therapies have emerged as an innovative and promising alternative to traditional drugs, being explored for the treatment of liver fibrosis diseases. Natural nanomaterials (including extracellular vesicles) and synthetic nanomaterials (including inorganic nanomaterials and organic nanomaterials) are developed to facilitate drug targeting delivery and combination therapy. In this review, the pathological features of liver fibrosis and the current anti-fibrosis drugs in clinical trials are briefly introduced, followed by a detailed introduction of the therapeutic nanoagents for the precise delivery of anti-fibrosis drugs. Finally, the future development trend in this field is discussed.
Patients in the control group will receive regular diets and metformin 1500 mg daily for 12 weeks. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
A transdermal therapeutic system for the delivery of an active ingredient across the skin and/or a mucosal surface. The system consists of at least one active ingredient as a solid dispersion in a common matrix with at lease one structuring agent and at least one destructuring agent. In particular the solid dispersion is a molecular dispersion in an inert carrier. Possible active ingredients include hormones, immunomodulators, immunosuppressants, antibiotics, cytostatics, diuretics, gastrointestinal agents, cardiovascular agents, and neuropharmaceuticals. Possible destructuring agents include carboxamides, and possible structuring agents include polyols, sugar alcohols, and sugars, or mixtures thereof. Possible matrixes include sheet-like adhesive pieces of material, plasters, patches, gels, ointments, creams, emulsions, embrocations, paints and impregnated fabrics. Also disclosed is a composition for transdermal administration comprised as above, where the structuring agent is of formula 1, where R1 and R2 are identical or different (C1-C6) Alkyl radicals, and R3 is a hydroxy-(C1-C6)alkyl radical.
The study is a randomized crossover trial. Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn). Throughout each visit, blood will be collected for nicotine analysis via an IV catheter placed in the patient's arm. Blood samples will be aliquoted into two separate vials. One will be analyzed for the current study and one will be placed in a biospecimen repository if participant provides consent for biorepository. Puff topography will be collected passively throughout the session to measure puffing patterns. Participants will complete self-report measures of nicotine withdrawal and craving. Finally, breath samples will be collected to measure changes in exhaled carbon monoxide, a potent lung toxicant, pre- and post-product use. At the final visit, participants will complete a behavioral economics concurrent choice task (see below for description) to behaviorally measure their decisions regarding use of e-cigarettes or heat not burn products in place of cigarettes. Finally, participants will be contacted by phone 6 months following the conclusion of visit 3 (or study discontinuation) to complete a phone survey. The objective of this survey is to assess for ongoing use of study products and is part of safety monitoring. We have no hypotheses related to the follow-up.
Cutaneous leishmaniasis (CL), a neglected tropical disease, is a major public health concern in Yemen, with Leishmania tropica identified as the main causative agent. This study aims to investigate the occurrence and distribution of Leishmania parasites in domestic and wild animals in CL endemic areas in the western highlands of Yemen. A cross-sectional study was conducted in the Utmah District of western Yemen. Blood and skin scraping specimens were collected from 122 domestic and wild animals and tested for the Leishmania DNA using internal transcribed spacer 1 (ITS1) nested polymerase chain reaction. Phylogenetic analyses were performed on 20 L. tropica sequences obtained from animals in this study and 34 sequences from human isolates (collected concurrently from the same study area) retrieved from the GenBank. Overall, L. tropica was detected in 16.4% (20/122) of the examined animals, including 11 goats, two dogs, two bulls, one cow, one donkey, one rabbit, one rat and one bat. None of the examined cats and sheep was positive. The animal sequences were segregated into four different L. tropica haplotypes, with the majority of the animal (15/20) and human (32/34) sequences composed of one dominant haplotype/genotype. These findings represent the first confirmed evidence of natural L. tropica infections in different kinds of domestic and wild animals in western Yemen, suggesting these animals potentially have a role in the transmission of CL in Yemen. Therefore, a One Health approach is required for the effective prevention and control of this devastating disease among endemic populations.
On the first oxytocin study day, participants will receive a 10 minute IV infusion of saline then one hour later will receive a 10 minute infusion of oxytocin 1.3 micrograms. On the second study day they will receive a 10 minute IV infusion of oxytocin 0.3 micrograms then one hour later will receive a 10 minute infusion of oxytocin 7 micrograms.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse reactions that appear to be related to drug use and for approximating rates.

The safety data presented in Table 1 reflect exposure to ketoconazole foam, 2% in 672 subjects, 12 years and older with seborrheic dermatitis. Subjects applied ketoconazole foam, 2% or vehicle foam twice daily for 4 weeks to affected areas on the face, scalp, and/or chest. Adverse reactions occurring in > 1% of subjects are presented in Table 1.

Application site reactions that were reported in <1% of subjects were dryness, erythema, irritation, paresthesia, pruritus, rash and warmth.
PURPOSE:To obtain a medicinal preparation, comprising a solid dispersion and improved in solubility of a sparingly soluble medicine by adding a hydrophilic polymer and a solubility improving adjuvant to the sparingly soluble medicine, pulverizing the resultant mixture in the presence of a small amount of an aqueous solvent and then removing the aqueous solvent. CONSTITUTION:This medicinal preparation is obtained by adding a hydrophilic polymer (e.g. hydroxypropyl methyl cellulose) and a solubility improving adjuvant (e.g. polyethylene glycol) to a sparingly soluble medicine, pulverizing the resultant mixture in the presence of an aqueous solvent (e.g. water) in an amount so as not to completely dissolve the sparingly soluble medicine, then removing the aqueous solvent by drying, etc., and providing a solid dispersion. The blending ratios based on 1 pt.wt. sparingly soluble medicine are 0.1-50 pts.wt. hydrophilic polymer, 0.1-10 pts.wt. solubility improving adjuvant and <=20 pts.wt. aqueous solvent. The medicinal preparation has high safety and can be produced without using a halogenated organic solvent at all and further applied to a wide range of the sparingly soluble medicines.
PURPOSE: To obtain a method for sepn. of blood components for obtaining plasma without contg. white cells and thick red cells. CONSTITUTION: The blood is taken into a master bag 1 by using a blood bag set made of a synthetic resin consisting of the master bag 1, a sub-bag 4 for taking the plasma and a sub-bag 5 for taking the thick red cells and is subjected to a centrifugal sepn. and thereafter, the master bag 1 is compressed from outside the master bag by means of three pieces of rectangular rods arranged in juxtaposition. The central rod of these rods is removed and while the master bag is held compressed from outside by means of two pieces of the remaining rods, a passage for taking the thick red cells is formed in the master bag and the blood in the master bag is compressed from outside the master bag. As a result, the respective layers of the plasma components and the thick red cell components are migrated into the respective sub-bags and only the buffy coat is made to remain in the master bag.
BACKGROUND: Anti-melanoma differentiation-associated gene 5 positive dermatomyositis (MDA5+ DM) is a life-threatening disease due to rapidly progressive interstitial lung disease (RP-ILD). We aimed to investigate the expression profile of T cell subsets in MDA5+ DM patients, seeking for possible disease-causing T cell subsets and potential biomarkers to distinguish ILD, especially RP-ILD patients.
METHODS: Peripheral blood T cell subpopulations were immunophenotyped in 24 MDA5+ DM patients and 21 healthy controls (HCs) by flow cytometry. The proportion of T cell subsets and clinical characteristics were analyzed. The quantitative determination of cytokines in the plasma was measured by using a microsphere-based immunofluorescence assaying kit.
RESULTS: The proportion of naïve and CD38+ T cells were much higher, whereas the proportion of central memory T cells were lower in MDA5+ DM patients than in HCs. Notably, the proportion of CD38+CD4+ T cells and CD38+CD8+ T cells on T cells in in RP-ILD group were significantly elevated compared to C-ILD, non-ILD group and HCs. Moreover, serum IFN-α levels were significantly increased in MDA5+ DM patients with RP-ILD. Further, the frequencies of CD38+CD4+ T cells and CD38+CD8+ T cells were positively correlated with IFN-α levels. Finally, ROC analysis indicated that CD38+CD4+ T cells and CD38+CD8+ T cells could be potential biomarkers for predicting ILD/RP-ILD in MDA5+ DM patients.
CONCLUSION: Dysregulated CD38 expression on T cell subsets was associated with lung involvement, especially RP-ILD in MDA5+ DM patients. CD38+ T cell subsets could be used as potential biomarkers for predicting ILD/RP-ILD in MDA5+ DM patients.